ADDF and Pfizer’s CTI Co-Fund New Alzheimer’s Project

The Alzheimer’s Drug Discovery Foundation (ADDF) and Pfizer’s Centers for Therapeutic Innovation (CTI) announced they will jointly support a new project that could result in a potential therapeutic to treat Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. The program is being led by Valina Dawson, PhD, and her team at Johns Hopkins University School of Medicine.

The collaboration between the ADDF and CTI was born at a Faster Cures “Partnering for Cures” conference, and it represents the increasingly important role of collaboration across industry, academia, and foundations in the drug discovery process. These collaborations are particularly critical in Alzheimer’s disease, which currently has no disease-modifying treatment options.

In addition to monetary support from CTI and the ADDF, Dr. Dawson and her project team will benefit from the comprehensive drug development expertise and resources of Pfizer’s CTI, as well as the ADDF’s disease knowledge. She will work closely with Dr. Paul Wes, Director at Pfizer’s CTI, and scientists from Pfizer’s Neuroscience, Medicinal Chemistry, Primary Pharmacology, and Drug, Safety, Research & Development units.

Dr. Uwe Schoenbeck, Senior Vice President of Pfizer’s External Science and Innovation group, explains: “By combining Dr. Dawson’s approach and expertise with Pfizer’s drug development expertise and resources, we hope to accelerate and optimize the development of a potential therapy to patients. The goal of this collaboration with the ADDF is to find the most promising new targets for treating Alzheimer’s and Parkinson’s and develop potential medicines against them as quickly as possible to the benefit of patients.”

Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF, says, “The ADDF has a vast wealth of knowledge about emerging targets in Alzheimer’s disease and the academic scientists pursuing them. CTI has access to resources that are necessary to create and develop drugs for human clinical trials. Our collaboration is built on our shared belief that Alzheimer’s disease can and will be treated, and we can get there faster if we work together.”